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The advancement and intensive use of chemotherapy in treating childhood cancers has led to a growing population of young
cancer survivors who face increased bone health risks. However, the underlying mechanisms for chemotherapy-induced skeletal
defects remain largely unclear. Methotrexate (MTX), the most commonly used antimetabolite in paediatric cancer treatment, is
known to cause bone growth defects in children undergoing chemotherapy. Animal studies not only have conﬁrmed the clinical
observations but also have increased our understanding of the mechanisms underlying chemotherapy-induced skeletal damage.
These models revealed that high-dose MTX can cause growth plate dysfunction, damage osteoprogenitor cells, suppress bone
formation, and increase bone resorption and marrow adipogenesis, resulting in overall bone loss. While recent rat studies have
shown that antidote folinic acid can reduce MTX damage in the growth plate and bone, future studies should investigate potential
adjuvant treatments to reduce chemotherapy-induced skeletal toxicities.
1.Introduction
During childhood and adolescence, bone continues to grow
until a peak height and peak bone mass are achieved. It
is during these periods that children are most vulnerable
to interference to skeletal growth, and disturbance to the
growing skeleton results from disruption to the processes of
endochondral ossiﬁcation and/or bone remodeling, which
may predispose children to earlier onset of skeletal defects.
Due to signiﬁcant advancements and higher survival rate,
cancer chemotherapy has been gaining popularity in treat-
mentofpaediatric cancersand has becomean important risk
factor for bone growth defects in paediatric cancer patients.
Intensive chemotherapy for childhood cancers has been
shown to cause bone growth defects (bone loss, osteopenia,
and fractures).
Methotrexate is the most commonly used antimetabolite
in childhood oncology, and both clinical and experimental
studies have demonstrated methotrexate-induced bone
growth impairment. This paper reviews previous studies in
which rat models of methotrexate chemotherapy have been
used to investigate chemotherapy-induced bone defects,
mechanisms of bone growth arrest and bone loss, and
recovery potential.
2.Bone GrowthandRegulation
Bone growth is the process involving fascinating changes
in morphology and biochemistry during development and
growth, which gradually ceases until adolescence ends. Dur-
ing bone growth in childhood and adolescence, lengthening
of long bones depends on the process of endochondral
ossiﬁcation, in which the growth plate cartilage continues
to produce calciﬁed cartilage which serves as a template for
formation of primary trabecular bone [1]. Growth plate is
situated at both ends of long bones, which is composed of2 Journal of Biomedicine and Biotechnology
three distinct zones: the resting, proliferative, and hyper-
trophic zones. Bone growth begins as progenitor cells at
resting zone are activated and enter the cell cycle at the pro-
liferative zone [2] and produce extracellular matrix rich in
collagen-IIandaggrecan[1].Thehypertrophicchondrocytes
secrete matrix rich in collagen-X and direct mineralisation
of their surrounding matrix while undergoing apoptosis [3].
Metaphyseal primary bone formation begins as blood vessels
invade the mineralised hypertrophic cartilage, which brings
in two cell types (osteoblasts and osteoclasts) that remodel
the mineralized cartilage to primary woven bone [1]. While
osteoclastsresorbthecalciﬁedcartilage,osteoblastspenetrate
the invaded calciﬁed cartilage and replace it with spongy
bone [1]. Bone lengthens as growth plate cartilage continues
to grow and is replaced by bone. Longitudinal bone growth
is mainly regulated by genetic and hormonal factors such as
growth hormone (GH), insulin-like growth factors (IGFs)
[4, 5], thyroid hormone and glucocorticoids, sex steroids
[6–8], ﬁbroblast growth factors (FGF), epidermal growth
factor and related ligands [9] transforming growth factor β
(TGF-β), and bone morphogenic protein (BMP) [10, 11].
However, environmental factors such as nutrition [12–14]
and medical treatments including chemotherapy have also
been shown to be important determinants for bone growth
in children, inﬂuencing the ﬁnal height and bone mass of an
individual.
3.The ClinicalIssueof Methotrexate-Induced
SkeletalDefects
Cancer chemotherapy has been achieving better success in
treatment of paediatric cancers, with a survival rate over
80% in treating acute lymphoblastic leukaemia (ALL) which
is the major childhood cancer. Consequently, childhood
chemotherapy has become an important risk factor for bone
growth defects in paediatric cancer patients. Methotrexate
(MTX) is the most widely used antimetabolite in the
treatment of childhood cancers and is critical for treating
acute lymphoblastic leukemia (ALL) [15]. MTX is a folate
antagonist, commonly used at high-doses for the treatment
of malignancies (100–1,000mg/m2)[ 16, 17]a n da tl o w e r
doses(5–25mg/week)forthetreatment ofinﬂammatory dis-
eases such as rheumatoid arthritis (RA) [17, 18]. Frequently
reported adverse eﬀects associated with high-dose MTX
includenausea, abdominal distress, intestinal mucositis [19],
leucopenia, and bone marrow suppression [20]. High-dose
MTX has also been shown to have signiﬁcant damaging
eﬀects on bone growth in children [21].
Clinical studies have highlighted osteopenia as a compli-
cation for childhood malignancies, characterised by reduced
BMD and increased fracture risks [21, 22]. During intensive
chemotherapy, children treated with high-dose MTX in
combination with corticosteroids showed depressed bone
formation and enhanced bone resorption [23, 24]. On the
other hand, some studies reported no signiﬁcant BMD
reduction in survivors of ALL [25]. Since ALL treatment
regimens are multiple drug combination therapies with
or without cranial irradiation, it is diﬃcult to determine
the eﬀects of high-dose MTX alone on bone growth.
However, high-doses of MTX and corticosteroid together
were found to be associated with longitudinal growth arrest
[26, 27], a high risk of low bone mass and failure for
BMD recovery even after discontinuation of treatment [25].
Overall,the use ofhigh-dose MTX intreating paediatric ALL
is encouraged; however, early onset of skeletal complications
must be monitored.
4.Mechanistic StudiesonMTXSkeletalDefects
withAnimal Models
The mechanism of how childhood cancer chemotherapy
aﬀects bone growth remains largely unknown. Since all ALL
treatment protocolsvary notonly in dosagebutalso, routeof
administration and use of cranial irradiation, it is diﬃcult to
distinguish the eﬀectsof individual chemotherapeutic agents
on bone growth. Hence, many laboratory studies have been
conducted which have enabled investigations into the eﬀects
and underlying mechanisms of diﬀerent chemotherapeutic
agents alone on bone growth. For example, in a rat
chemotherapy model, doxorubicin, an anthracycline antibi-
otic and cytotoxic (antineoplastic) agent commonly used
against various cancers, caused thinning of growthplate, dis-
turbance of chondrocyte columnar arrangement, increased
number of fat cells but decreased hematopoietic cellularity
i nt h eb o n em a r r o w[ 28]. Similarly, in vitro studies using
human bone marrow cells have shown that corticosteriods
(commonly used for treating ALL) can signiﬁcantly suppress
osteoblastic activity, resulting in decreased bone formation
[29]. Corticosteroid-induced osteopenia/osteoporosis has
been conﬁrmed in animal models [30], has been shown to
reducebonemineral density,andis associated with increased
fracture risks in children [31]. In this section, animal studies
investigating the mechanisms for MTX-induced skeletal
damage are reviewed.
4.1. Methotrexate Chemotherapy-Induced Growth Plate Dys-
function. As bone lengthening is the result of endochondral
ossiﬁcation at the growth plate, chemotherapy-induced
growth plate damage may impact on bone lengthening. An
earlier in vitro study examining eﬀects of chemotherapeutic
agents on chondrocyte proliferation observed no eﬀects of
MTXonproliferatingchondrocytes[32].Inaratstudy,MTX
at 60mg/m2 body surface area (injections once weekly given
for 8 weeks) was shown to have no eﬀects on proliferating
chondrocytes but to cause an increase in hypertrophic
zone thickness and number of hypertrophic chondrocytes
[33]. More recent animal studies revealed that while long-
term low-dose MTX treatment caused no damage to the
growth plate, two cycles of high-dose MTX (at 0.75mg/kg,
5d a y so n / 9d a y so ﬀ/5 days on) caused a signiﬁcant decrease
in growth plate height [34]( F i g u r e1), which was due
to the reduction of chondrocyte proliferation (Figure 1)
and collagen-II production, as well as the induction of
chondrocyte apoptosis possibly through the Fas/FasL death
receptor pathway [35]( F i g u r e1). Due to the growth plate
dysfunction, a signiﬁcant reduction in the thickness of newlyJournal of Biomedicine and Biotechnology 3
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Figure 1: Eﬀect of acute high-dose MTX chemotherapy on growth plate structure and cellular changes in young rats. H & E stained section
of a normal rat tibial growth plate (a) and an MTX-treated rat growth plate (b). Dashed line represents total heights of growth plates.
BrdU labeling showing proliferative chondrocytes in a normal rat (c) and an MTX-treated rat (d), with arrows pointing to proliferating
chondrocytes. Normal proliferative/hypertrophic chondrocytes of a normal rat (e) showing no apoptosis; MTX-treated rats with apoptotic
chondrocytes in lower proliferative/upper hypertrophic zone (f), and a magniﬁed view of apoptotic chondrocyte (g). (Images are from the
authors’ own lab and have not been published previously.)
formed primary spongiosa bone was also found in the
adjacent metaphyseal bone, mirroring the thinning of the
growth plate [35, 36]. These studies suggest that the eﬀect
of MTX on growth plate structure and function is largely
dependent on the treatment dose and regimen.
4.2. Damaging Eﬀects of Methotrexate Chemotherapy on Os-
teoblasts, Osteoprogenitors, and Stem Cells. High-dose MTX
(100–1000mg/m2) acts by reversibly inhibiting the enzyme
dihydrofolate-reductase (DHFR). DHFR is essential for the
synthesis of purine and thymidylate, thus inhibition of
DHFR can ultimately inhibit DNA synthesis and therefore
cell proliferation [17]. Osteoblast number and function are
important indicators of bone formation and bone mass. Ear-
lier studies which analysed the eﬀects of MTX chemotherapy
on bone metabolism revealed that MTX has an inhibitory
eﬀect on osteoblast function without altering osteoblast
numbers in vivo [37]. Another study demonstrated that4 Journal of Biomedicine and Biotechnology
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Figure 2: Mesenchymal stem cell commitment and eﬀects of MTX chemotherapy in bone marrow adiposity. Multipotency of the
mesenchymal stem cell (a), illustrated by the capacity to diﬀerentiate down a number of cell lineages. H & E stained bone marrow section
taken from a control rat (b) and from an acute high-dose MTX-treated rat (c) showing adipocyte-rich bone marrow. (Images are from the
authors’ own lab and have not been published previously.)
MTX-induced osteoblastic damage led to a diminished
mineralizing surface, mineral apposition rate, and bone
formation rate [38]. Consistently, an in vitro study using
mouse osteoblasts in culture showed that MTX can decrease
osteoblastic cell function in a dose-dependent manner, as
indicated by a reduction of matrix calciﬁcation and super-
natant osteocalcin levels [39]. Althoughearlier studiesfound
no obvious changes in osteoblast density after MTX treat-
ment in rats, more recent studies reported that both acute
high-dose and chronic low-dose MTX treatment in rats can
reduceosteoblastdensityontrabecularbonesurface [34,36].
Osteoblasts are derived from stromal progenitor cells
or mesenchymal stem cells (MSCs), which can diﬀerentiate
into osteogenic, chondrogenic, or adipogenic cells [40]
(Figure 2). The osteogenic ability of these cells makes it
possible to study the toxicity ofchemotherapy alone on bone
marrowosteoprogenitorcell populationand theirosteogenic
potential.Previously,high-dosechemotherapy (inabsenceof
irradiation) was found to have a direct eﬀect on the stromal
population in patients undergoing chemotherapy, caused
depletion of bone marrow progenitor cells [41], and resulted
in decreased osteoblast diﬀerentiation and bone formation
[41, 42]. Recently, rat models of MTX chemotherapy also
demonstrated a reduction in bone marrow osteoprogenitor
cells and suppressed stromal progenitor cell proliferation
[34, 36]. These in vivo studies suggest that chemotherapy
with several drugs in combination or with MTX alone
impairs the oestrogenic commitment of the bone marrow
progenitor cell population, the severity and recovery of
which are major determinants of the extent of bone loss and
recovery potential following chemotherapy.
In vitro studies found that human bone marrow MSCs
appear more resistant to MTX, cyclophosphomide and
busulphan than peripheral blood mononuclear cells [43],
and that isolated MSCs from normal or chemotherapy-
exposed patients remain unaﬀected by the presence of
cytotoxic agents in culture when assessed for diﬀerentiation
or proliferative potential [44]. These studies suggest that
while the already committed osteoprogenitor cells can be
more easily aﬀected by chemotherapy drugs, the quiescent
MSCs appear to have the capacity to maintain their number
and their stem cell character both in vivo and in vitro
in response to some chemotherapeutic agents [44]. This
p e r h a p se x p l a i n sw h yt h eb o n ea n db o n em a r r o ws t r o m a
can regenerate in the MTX acute treatment models in rats
[34–36].
4.3. Methotrexate Chemotherapy-Induced Marrow Adiposity.
In recent rat studies of MTX chemotherapy-induced bone
defects, it has been found that apart from the reduced
osteoblast number and trabecular bone volume, there is a
signiﬁcant increase in marrow adiposity [35, 36]( F i g u r e2).Journal of Biomedicine and Biotechnology 5
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Figure 3:Eﬀect ofMTXchemotherapy onosteoclastdensityinyoungrats.H &Estainedsectionsshowingosteoclastsalongtrabecular bone
surface inacontrolrat(a)andanMTX-treated rat(b),witharrowspointingto multinucleated osteoclasts.TRAP-stained osteoclastsformed
ex vivo from bone marrow cells of a control rat (c) and an MTX-treated rat (d), with arrows pointing to multinucleated TRAP+ osteoclasts.
(Images are from the authors’ own lab and have not been published previously.)
Consistently, one early in vitro study demonstrated that
the presence of MTX can signiﬁcantly increase the num-
ber of fat-containing cells in bone marrow culture [45].
These studies suggest that MTX chemotherapy can cause
a reciprocal switch in bone versus fat volume in the bone
marrow microenvironment.Sinceadipocytesandosteoblasts
share a common precursor (bone marrow MSC), it has been
proposedthat boneloss may resultfrom a switch in favourof
adipocyte diﬀerentiation over osteoblast commitment. Since
the Wnt signalling pathway stimulates osteoblast lineage
commitment and inhibits adipocyte formation [46, 47], it is
ofinterest to examine whether deregulation ofWnt signaling
may be involved in this bone/fat reciprocal relationship
following MTX chemotherapy.
4.4. Eﬀects of Methotrexate on Haematopoietic Cells and
Osteoclast Formation. In addition to the damage to
osteoblasts, bone marrow stromal cells (discussed above),
haematopoietic stem cells (HSCs), and haematopoiesis [48],
another possible mechanism for chemotherapy-induced
decrease in bone mass in children is the increased formation
of bone resorptive cells (osteoclasts) and the alteration to
the bone remodeling balance in favour of bone resorption.
Clinically, children undertaking high-dose MTX treatment
have lower bone mass, with increased urinary and faecal
calcium excretion, suggesting increased bone resorption
[24, 49]. Results from both short- and long-term rat studies
revealedthatMTX cancause anincrease inosteoclastdensity
on trabecular bone surface [34, 38, 50]( F i g u r e3). Similarly,
an increase in the number of empty Howship lacunae on
the trabecular surface [51] and excretion of hydroxyproline
[50] following MTX administration are evident in animal
studies which further support the argument of increased
bone resorption. A recent ex vivo study using bone marrow
cells obtained from rats treated with MTX showed an
increase in the osteoclast precursor cell pool which express
surface marker CD11b+ and an increase in ex vivo osteoclast
formation [34]( F i g u r e3). Mac-1 (CD11b/CD18) has
been shown to play a role in facilitating the diﬀerentiation
of osteoclast precursors into mature osteoclasts when
stimulated by the key osteoclastogenic cytokine RANKL
[52]. Collectively, this indicates that MTX chemotherapy
aﬀects osteoclastogenesis at the precursor level.
Some clinical data revealed an increased serum level of
proinﬂammatory cytokine TNF-α in patients undergoing
chemotherapy [53], suggests a potential role for proin-
ﬂammatory cytokines in chemotherapy-induced osteoclas-
togenesis. It is known that, apart from RANKL, osteoclast
diﬀerentiation and activity can be enhanced by proinﬂam-
matory mediators such as IL-1, IL-6, and TNF-α [54].
Whilst increased precursor and mature osteoclast presence
within the bone strongly suggests increased resorptive
activity, no animal studies have directly investigated this
link in chemotherapy model. Future studies are required to
investigate the potential role of proinﬂammatory cytokines
in osteoclastogenesis as well as the mechanisms by which6 Journal of Biomedicine and Biotechnology
MTX chemotherapy may induce an inﬂammatory response
within the bone marrow microenvironment.
5.Conclusionsand FuturePerspectives
As longitudinal bone growth occurs during childhood and
adolescence,alteredbonemetabolismduringthisperiodmay
interfere with bone growth and bone mass accrual, which
may result in lower peak bone mass, potentially leading
to premature onset of osteopenia and increased fracture
risk [55]. The advancement and success of chemotherapy
in treating childhood cancers (particularly ALL) and thus
its increasing use in paediatric oncology have resulted in a
growingpopulationofyoungcancersurvivorswithincreased
bonehealthrisks (reducedbonegrowthand lowerpeak bone
mass). Although the mechanism for chemotherapy-induced
bone damage is multifactorial, recent research has revealed
that chemotherapeutic agents can directly impair bone
growth. In particular, rat studies have conﬁrmed that MTX
can directly disrupt the growth plate structure and function
by inducing chondrocyte apoptosis. reducing chondrocyte
proliferation and cartilage protein synthesis. Dysfunction of
the growth plate, therefore, reduces formation of primary
woven bone. Direct damage to osteoblasts by decreasing
osteoblast activity/formation (possibly through inducing the
switch in the bone marrow stromal cells towards adipogenic
diﬀerentiation at the expense of osteogenesis) and bone
marrow osteoprogenitor cells also contributes to reduced
bone formation. In addition, MTX chemotherapy has also
been shown to increase osteoclast formation and cause
aggravated bone resorption, contributing to the associated
bone loss.
Given the increased rates of fractures and early onset
of osteopenia in childhood survivors of ALL, future studies
should investigate strategies to reduce skeletal toxicities and
improve quality of life of chemotherapy patients. Currently,
recommendations and therapeutic strategies for reducing
childhood bone loss during chemotherapy are limited, and
there have been few studies investigating potential adjuvant
treatments to reduce chemotherapy-induced skeletal toxici-
ties. In this context, the rat models of MTX chemotherapy
have also been shown to be useful in demonstrating that
folinic acid, an antidote used clinically to reduce toxicity
to soft tissues such as gut and bone marrow haematopoi-
etic cells, is also eﬃcacious to reduce or prevent MTX
chemotherapy-induced bone growth defects [34].
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